ArticleArchives of pharmacal research2021
Kaempferol sensitizes cell proliferation inhibition in oxaliplatin-resistant colon cancer cells.
Article in Archives of pharmacal research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Bibliometric and visual analysis of global publications on kaempferol.Frontiers in nutrition · 2024Pooled it
- Anticancer Potentials of the Lignan Magnolin: A Systematic Review.Molecules (Basel, Switzerland) · 2023Pooled it
- Molecular Mechanisms of the Anticancer Activity of the Flavonoid Kaempferol: A Comprehensive Review.Journal of cancer prevention · 2026Review
- 3,3'-Di-O-methylellagic Acid Isolated fromPharmaceuticals (Basel, Switzerland) · 2026Article
- Natural defense against colorectal cancer: the effects of kaempferol on epigenetics, apoptosis, inflammation, oxidative stress, and cell proliferation.Frontiers in pharmacology · 2026Review
- RSK2 and its binding partners: an emerging signaling node in cancers.Archives of pharmacal research · 2025Review
- Clinical research, mechanisms, and prospects of flavonoids from HerbaFrontiers in pharmacology · 2025Review
- Research progress on the anti-tumor effects of euphorbia humifusa.Discover oncology · 2024Review
- The Anticancer Effects and Therapeutic Potential of Kaempferol in Triple-Negative Breast Cancer.Nutrients · 2024Review
- Synergistic Mechanisms of Selected Polyphenols in Overcoming Chemoresistance and Enhancing Chemosensitivity in Colorectal Cancer.Antioxidants (Basel, Switzerland) · 2024Review
- Implications of inflammatory cell death-PANoptosis in health and disease.Archives of pharmacal research · 2024Review
- Ribosomal S6 kinase 2-forkhead box protein O4 signaling pathway plays an essential role in melanogenesis.Scientific reports · 2024Article
- Research progress of Paris polyphylla in the treatment of digestive tract cancers.Discover oncology · 2024Review
- The Anticancer Potential of Kaempferol: A Systematic Review Based on In Vitro Studies.Cancers · 2024Review
- Effects and Mechanisms of Kaempferol in the Management of Cancers through Modulation of Inflammation and Signal Transduction Pathways.International journal of molecular sciences · 2023Review
- Article
- Exploiting Polyphenol-Mediated Redox Reorientation in Cancer Therapy.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Kaempferol: A potential agent in the prevention of colorectal cancer.Physiological reports · 2022Review
- The GenusFrontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
Abstract
Resolution to chemoresistance is a major challenge in patients with advanced-stage malignancies. Thus, identification of action points and elucidation of molecular mechanisms for chemoresist human cancer are necessary to overcome this challenge. In this study, we provide important evidence that kaempferol targeting RSKs might be a strategy to reduce the oxaliplatin-resistant colon cancer cells. We found that MAPK and PI3K-AKT signaling were increased in oxaliplatin (Ox)-resistant HCT116 (HCT116-Ox
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.